Protagenic Therapeutics, Inc. (PTIX)
$0.372
+0.05 (+16.21%)
Rating:
Recommendation:
-
| Symbol | PTIX |
|---|---|
| Price | $0.372 |
| Beta | 0.200 |
| Volume Avg. | 0.02M |
| Market Cap | 6.430M |
| Shares () | - |
| 52 Week Range | 0.3111-1.05 |
| 1y Target Est | - |
| DCF Unlevered | PTIX DCF -> | |
|---|---|---|
| DCF Levered | PTIX LDCF -> | |
| ROE | -44.83% | Strong Sell |
| ROA | -46.58% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 11.82% | Neutral |
| P/E | -1.77 | Sell |
| P/B | 0.87 | Buy |
Latest PTIX news
About
Download (Excel)Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.